- Home
- ERIC vs BIIB Comparison
ERIC vs BIIB Comparison
Compare ERIC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERIC
- BIIB
- Stock Information
- Founded
- ERIC 1876
- BIIB 1978
- Country
- ERIC Sweden
- BIIB United States
- Employees
- ERIC N/A
- BIIB N/A
- Industry
- ERIC Radio And Television Broadcasting And Communications Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ERIC Technology
- BIIB Health Care
- Exchange
- ERIC Nasdaq
- BIIB Nasdaq
- Market Cap
- ERIC 27.1B
- BIIB 25.1B
- IPO Year
- ERIC N/A
- BIIB 1991
- Fundamental
- Price
- ERIC $7.99
- BIIB $146.79
- Analyst Decision
- ERIC Hold
- BIIB Buy
- Analyst Count
- ERIC 1
- BIIB 27
- Target Price
- ERIC $6.70
- BIIB $252.20
- AVG Volume (30 Days)
- ERIC 16.1M
- BIIB 1.5M
- Earning Date
- ERIC 01-21-2025
- BIIB 02-11-2025
- Dividend Yield
- ERIC 3.18%
- BIIB N/A
- EPS Growth
- ERIC N/A
- BIIB 10.05
- EPS
- ERIC N/A
- BIIB 11.06
- Revenue
- ERIC $24,338,391,784.00
- BIIB $9,607,500,000.00
- Revenue This Year
- ERIC N/A
- BIIB N/A
- Revenue Next Year
- ERIC $3.22
- BIIB N/A
- P/E Ratio
- ERIC N/A
- BIIB $13.27
- Revenue Growth
- ERIC N/A
- BIIB N/A
- 52 Week Low
- ERIC $4.77
- BIIB $146.58
- 52 Week High
- ERIC $8.62
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- ERIC 40.37
- BIIB 23.28
- Support Level
- ERIC $8.21
- BIIB $148.60
- Resistance Level
- ERIC $8.35
- BIIB $154.24
- Average True Range (ATR)
- ERIC 0.12
- BIIB 3.89
- MACD
- ERIC -0.03
- BIIB -0.31
- Stochastic Oscillator
- ERIC 0.00
- BIIB 1.15
About ERIC Ericsson
Ericsson provides telecom equipment and services that are primarily used to build and facilitate mobile networks through operations in three segments: networks, cloud and software services, and enterprises. The firm's customers have historically been primarily wireless carriers, but the firm is making a push to cater more to other enterprises as well, both as they try to take advantage of 5G capabilities and on other "as-a-service" communications platforms. The company also licenses its patents to handset manufacturers so their devices are compatible with wireless networks.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.